ArticleOncoimmunology2016
The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Preclinical study of reirradiation with hyperthermia in recurrent murine tumors and normal mouse skin.Acta oncologica (Stockholm, Sweden) · 2025Article
- Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting course.Clinical and translational radiation oncology · 2025Review
- Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting.Biomolecules · 2023Review
- Combination Therapy of Radiation and Hyperthermia, Focusing on the Synergistic Anti-Cancer Effects and Research Trends.Antioxidants (Basel, Switzerland) · 2023Review
- Review
- Combined Hyperthermia and Re-Irradiation in Non-Breast Cancer Patients: A Systematic Review.Cancers · 2023Review
- Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.Pharmaceutics · 2023Review
- Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Article
- Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches.British journal of clinical pharmacology · 2020Review
- Brachytherapy in a Single Dose of 10Gy as an "in situ" Vaccination.International journal of molecular sciences · 2020Article
- Effects of Radiation on the Tumor Microenvironment.Seminars in radiation oncology · 2020Review
- Immune biological rationales for the design of combined radio- and immunotherapies.Cancer immunology, immunotherapy : CII · 2020Review
- Enhancing the efficacy of immunotherapy using radiotherapy.Clinical & translational immunology · 2020Review
- Immunomodulation of NK Cells by Ionizing Radiation.Frontiers in oncology · 2020Review
- Review
- Review
- Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment.Frontiers in oncology · 2019Article
- Radiation, inflammation and the immune response in cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical tumor therapy consists of surgery, radio(RT)- and/or chemotherapy. Additive immunotherapy has gained in impact and antitumor in situ immunization strategies are promising to strengthen innate and adaptive immune responses. Immunological effects of RT and especially in combination with immune stimulation are mostly described for melanoma. Since hyperthermia (HT) in multimodal settings is capable of rendering tumor cells immunogenic, we analyzed the in vivo immunogenic potential of RT plus HT-treated B16 melanoma cells with an immunization and therapeutic assay. We focused on the role of natural killer (NK) cells in the triggered antitumor reactions. In vitro experiments showed that RT plus HT-treated B16 melanoma cells died via apoptosis and necrosis and released especially the danger signal HMGB1. The in vivo analyses revealed that melanoma cells are rendered immunogenic by RT plus HT. Especially, the repetitive immunization with treated melanoma cells led to an increase in NK cell number in draining lymph nodes, particularly of the immune regulatory CD27(+)CD11b(-) NK cell subpopulation. While permanent NK cell depletion after immunization led to a significant acceleration of tumor outgrowth, a single NK cell depletion two days before immunization resulted in significant tumor growth retardation. The therapeutic model, a local in situ immunization closely resembling the clinical situation when solid tumors are exposed locally to RT plus HT, confirmed these effects. We conclude that a dual and time-dependent impact of NK cells on the efficacy of antitumor immune reactions induced by immunogenic tumor cells generated with RT plus HT exists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.